Where is BioXcel located?

BioXcel is headquartered in Branford, United States. It is registered at Guilford, Connecticut.

Who is the current CEO of BioXcel?

Bhavish Aggarwal, Garrett Camp, Ryan Hoover, Sam Lessin, Scott Marlette, Gary Little, Abida Nikam and Vimal Mehta s of BioXcel. Ryan Hoover is also angel investors in 18 startups, including Product Hunt.

How many employees does BioXcel have?

As of Jul 01, 2024, the latest employee count at BioXcel is 56.

Is BioXcel a funded company?

BioXcel is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does BioXcel rank among its competitors?

BioXcel ranks 55th amongst 141 active competitors, of which 61 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was XtalPi, which secured $268M in Sep, 2025.

Who are the top competitors of BioXcel?

BioXcel's top competitors include Recursion Pharmaceuticals, XtalPi and Schrodinger. Among them, XtalPi secured the most recent funding round in September, 2025.

BioXcel - 2026 Company Profile, Team, Funding & Competitors

BioXcel is a funded company based in Branford (United States), founded in 2006 by Bhavish Aggarwal, Garrett Camp, Ryan Hoover, Sam Lessin, Scott Marlette, Gary Little, Abida Nikam, Krishnan Nandabalan and Vimal Mehta. It operates as an AI-powered drug discovery and development for transformative medicines. The company has 141 active competitors, including 61 funded and 10 that have exited. Its top competitors include companies like Recursion Pharmaceuticals, XtalPi and Schrodinger.

Company Details

AI-powered drug discovery and development for transformative medicines. This organization utilizes artificial intelligence to accelerate the development of innovative medicines across multiple therapeutic areas with high unmet needs. Their AI-enabled platform, EvolverAI, reduces development costs and accelerates drug discovery timelines. They combine in-house human expertise with technological advancement to change the paradigm of drug discovery. The company focuses on creating breakthroughs in various disease categories. They are involved in research and innovation focused on developing transformative treatments. They use a real-time cloud-based pharma analytics platform revolutionizing decision-making. The platform provides live intelligence on treatment paradigms, product opportunities, key market movers, product blueprints, portfolio impact, and commercial launch scenarios. The suite's cognitive insights help identify potential market winners and streamline internal and external innovation, enabling better R&D prioritization and sound investment decisions.

Website: bioxcel.com
Social
Email ID: *****@bioxcel.com
Phone Number: +1 **********
Registered Address: Guilford, Connecticut

Key Metrics

Founded Year

2006

Location

Branford, United States

Stage

Funding Raised

Investors

Gore Range Capital

Ranked

55^th among 141 active competitors

Employee Count

56 as on Jul 01, 2024

Similar Companies

Recursion Pharmaceuticals & 170 more

View BioXcel's full profile

BioXcel is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bioxcel Corporation CIN: 202612128 , United States, Active	Dec 31, 1999	-	21 (As on Dec 31, 2022)	-
BioXcel Therapeutics, Inc CIN: 821386754 , United States, Active		-	-	-
E Z BIOXCEL SOLUTIONS PRIVATE LIMITED CIN: U93100DL2005PTC142826 , India, Active	Nov 22, 2005	$1.4M (As on Mar 31, 2024)	-

BioXcel is a funded company. BioXcel has 1 institutional investor.

View details of BioXcel's funding rounds and investors

The founders of BioXcel are Bhavish Aggarwal, Garrett Camp, Ryan Hoover, Sam Lessin, Scott Marlette, Gary Little, Abida Nikam, Krishnan Nandabalan and Vimal Mehta. Scott Marlette and Bhavish Aggarwal are the CEOs of BioXcel.

Here are the details of BioXcel's key team members:

Bhavish Aggarwal: Co-Founder & CEO of BioXcel and founder of 15 other companies, including Ola Maps, Krutrim and Krutrim Ai Designs. They are also an angel investor in 14 startups and serve on the boards of 4 companies.
Contact Info: 1 phone number
Garrett Camp: Co-Founder & CEO of BioXcel and founder of 8 other companies, including SeriesG, Mix and UberEATS. They are also an angel investor in 7 startups and serve on the board of 1 company.
Ryan Hoover: Co-Founder & CEO of BioXcel and founder of 1 other company. They are also an angel investor in 18 startups.
Contact Info: 1 email address
Sam Lessin: Co-Founder & CEO of BioXcel and founder of 3 other companies, Slow Ventures, Fin and Dropio. They are also an angel investor in 8 startups.
Contact Info: 1 email address
Scott Marlette: Co-Founder & CEO of BioXcel and founder of 2 other companies, Slow Ventures and GoodRx. They are also an angel investor in 3 startups.
Contact Info: 2 email addresses

View details of BioXcel's Founder profiles and Board Members

BioXcel's employee count trend

BioXcel has 56 employees as of Jul 24. Here is BioXcel's employee count trend over the years:

Uncover BioXcel's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioXcel include Recursion Pharmaceuticals, XtalPi and Schrodinger. Here is the list of Top 10 competitors of BioXcel, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, DCVC & 46 others	72/100
2nd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
3rd	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates Foundation, WuXi AppTec & 16 others	66/100
4th	Healx 2014, Cambridge (United Kingdom), Series C	AI-powered drug discovery platform to treat rare diseases	$115M	Atomico, Balderton Capital & 17 others	64/100
5th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	Sequoia Capital China, Luminous Ventures ... & 13 others	63/100
6th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
7th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	62/100
8th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Warburg Pincus & 36 others	62/100
9th	Aqemia 2019, Paris (France), Series A	Provider of an AI and quantum physics to discover therapeutic molecules	$103M	Eurazeo, Bpifrance & 4 others	62/100
10th	Isomorphic Labs 2021, London (United Kingdom), Series D	AI-driven platform to accelerate drug discovery process	$600M	Thrive Capital, Alphabet & 1 others	62/100
55th	BioXcel 2006, Branford (United States), Funding Raised	AI-powered drug discovery and development for transformative medicines	-	Gore Range Capital	36/100